Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 3/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28125253 | 1.00 | CA1 (0.37) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL5973232 | 0.89 | KMT2A (0.41) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL29173690 | 0.89 | KMT2A (0.41) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL30983360 | 0.87 | KMT2A (0.38) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL28124873 | 0.87 | KMT2A (0.38) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL28124455 | 0.87 | KMT2A (0.42) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL16060617 | 0.87 | KMT2A (0.42) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL28124396 | 0.86 | KMT2A (0.43) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL17079656 | 0.86 | KMT2A (0.43) | CA1CA2KMT2ACASP3FABP5 | |
| SCHEMBL28124397 | 0.85 | KMT2A (0.45) | CA1CA2KMT2ACASP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152225-B1 | PEPTIDES AS OXYTOCIN AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-11-14 | — | — | EP | disclosed |
| EP-3152225-A1 | PEPTIDES AS OXYTOCIN AGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170081368-A1 | PEPTIDES AS OXYTOCIN AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2017-03-23 | — | — | US | disclosed |
| WO-2015185584-A1 | PEPTIDES AS OXYTOCIN AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081368-A1 | PEPTIDES AS OXYTOCIN AGONISTS | OXTR, AVPR1B, AVPR1A | CA1 3951/4885CA2 4871/4885KMT2A 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.